Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18651970 | 0.87 | ADRB3 (0.79) | ADRB3ADRB1ADRB2 | |
| SCHEMBL12576743 | 0.86 | KCNH2 (0.72) | KMT2AKCNH2ADRB3ADRB1ADRB2 | |
| SCHEMBL15451481 | 0.82 | ADRB3 (0.66) | KMT2AMEN1KCNH2MAPTMAPK1 | |
| SCHEMBL15275450 | 0.79 | ADRB3 (0.76) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL11376334 | 0.78 | KMT2A (0.56) | KMT2AMEN1KCNH2MAPTMAPK1 | |
| SCHEMBL9683368 | 0.77 | ADRB3 (0.74) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL9683373 | 0.77 | ADRB3 (0.74) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL7116296 | 0.77 | ADRB3 (0.79) | KMT2AMEN1ADRB3ADRB1ADRB2 | |
| SCHEMBL27478454 | 0.76 | ADRB1 (0.78) | KMT2AMEN1ADRB3ADRB1ADRB2 | |
| SCHEMBL4009687 | 0.76 | KMT2A (0.60) | KMT2AMEN1KCNH2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KMT2A 701/4885MEN1 3627/4885KCNH2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.